Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498291 | 1.00 | TSHR (0.41) | TSHRMAPK14KMOALDH1A1KDM4E | |
| SCHEMBL22163322 | 0.94 | TSHR (0.40) | TSHRMAPK14KMOALDH1A1KDM4E | |
| SCHEMBL29498294 | 0.85 | KDM4E (0.42) | MAPK14ALDH1A1KDM4EBRAFEPHX2 | |
| SCHEMBL17434781 | 0.85 | KDM4E (0.42) | MAPK14ALDH1A1KDM4EBRAFEPHX2 | |
| SCHEMBL29498277 | 0.83 | MAPK13 (0.40) | MAPK14ALDH1A1KDM4EHTR2AHTR2C | |
| SCHEMBL17434775 | 0.83 | MAPK13 (0.40) | MAPK14ALDH1A1KDM4EHTR2AHTR2C | |
| SCHEMBL26016891 | 0.82 | KDM4E (0.40) | MAPK14ALDH1A1KDM4EBRAFEPHX2 | |
| SCHEMBL9943575 | 0.80 | MAPK14 (0.44) | TSHRMAPK14KMOALDH1A1KDM4E | |
| SCHEMBL17434778 | 0.78 | RUNX1 (0.41) | TSHRMAPK14KMOALDH1A1KDM4E | |
| SCHEMBL22163147 | 0.76 | NPC1 (0.41) | TSHRMAPK14KMOALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | claimed |
| EP-3169328-B1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2022-03-09 | — | — | EP | claimed |
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2019-10-08 | — | — | US | claimed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | claimed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | claimed |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | ABIVAX (FR) | 2025-01-21 | — | — | US | disclosed |
| EP-3998070-B1 | MIR-124 AS A BIOMARKER FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2024-12-18 | — | — | EP | disclosed |
| CN-117568459-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117379426-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117281805-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-117205212-A | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX公司 | 2023-12-12 | — | — | CN | disclosed |
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2019-10-08 | — | — | US | disclosed |
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (FR) | 2019-10-08 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2017-07-20 | — | — | US | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
| EP-2974729-A1 | Quinoline derivatives for use in the treatment of inflammatory diseases | ABIVAX (FR) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435370-B2 | Quinoline derivatives for the treatment of inflammatory diseases | NR1I3, NR3C2, NR1I2 | TSHR 2525/4885MAPK14 2482/4885KMO 676/4885 |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | CD14, MYADM, SYNCRIP | TSHR 3974/4885MAPK14 256/4885KMO 4283/4885 |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SSB, SYVN1, TLR7 | TSHR 2604/4885MAPK14 705/4885KMO 1129/4885 |
| US-20170204063-A1 | QUINOLINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | NR1I2, NR3C2, NR1I3 | TSHR 2433/4885MAPK14 2556/4885KMO 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.